Dave Chenn is the founder, CEO, and managing partner of Oceanpine Capital. See sector focus and contact routes.
Dave Chenn is the founder, CEO, and managing partner of Oceanpine Capital, a venture capital firm he established in 2018 in Hong Kong after over twenty years in entrepreneurship and investment at firms like McKinsey and Oracle. He leads more than $2 billion in investments across technology and healthcare, targeting both early-stage and late-stage ventures globally with a focus on TMT, consumption upgrade, advanced manufacturing, and healthcare sectors. While specific check sizes and lead/follow behavior are not publicly detailed, his firm has backed companies with rounds up to $65 million, such as Apexigen. Notable portfolio companies include Horizon Robotics, Enflame, Tiger Brokers (which exited), and Ansun BioPharma. Chenn does not appear to have published a distinctive public investment thesis or writing, though he is recognized for his forward-looking strategic vision and extensive global network. His profile emphasizes deep industry resources and a commitment to supporting technology enterprises through partnerships with top institutions like Hillhouse Capital as a limited partner.
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in Central.
Investors like Dave Chenn · Full investor directory · Investor access · Company funding database